30 closest matches · ranked by relevance
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Cannabis Dependence
Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Substance Use Disorders · HIV · Depression
Primary: Change in Mental Health and Substance Use Screening Rates — 2008; 2379 Participants
Substance-related Disorders
Primary: Treatment Completion — 43; 31 Number of women — p=<0.05
Opioid-use Disorder · Cocaine Use Disorder · Marijuana Use Disorder
Primary: Retention — 4; 27; 10; 21 Participants
Amphetamine Abuse · Amphetamine Dependence · Bipolar Disorder
Primary: Depression Symptoms — 26.2; 33.1 scores on a scale — p=0.05
Dual Diagnosis
Primary: Psychiatric Functioning at 6 Months — .333; .387 units on a scale
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
Methamphetamine Abuse · Opioid-use Disorder · HIV Seropositivity
Primary: Increase in HIV Viral Suppression for HIV-positive Participants: High- vs. Low-Intensity Frontline Intervention With SMS in Stage 2 — 31; 35; 6; 3 Participants — p=0.447
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Cocaine Use Disorder
Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
Cannabis · Cannabis Use
Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale
Opioid-use Disorder
Primary: Adherence to Medication Assisted Treatment (MAT) — 32; 17 Participants
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
Posttraumatic Stress Disorders · Combat Disorders · Alcohol Dependence
Primary: Change in Post-traumatic Stress Disorder Symptomatology — -51.2; -35.9; -22.3; -10.9 score on a scale
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Substance Use Disorders
Primary: Any Cannabis Abstinence — 13; 18 participants
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Cannabis Use Disorder
Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds
Substance Use · Psychopathy
Primary: Percent Days Abstinent Per Month From Drug Use — 46.92; 55.16 percentage of days abstinent — p=.02
Drug Use · Alcohol Use · Congestive Heart Failure
Primary: Change in Substance Use Rates From Baseline — 51.37; 51.38; 35.53; 26.65 Days of Substance Use
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
Cocaine Use Disorder
Primary: % Cocaine-Negative Urine Specimens Per Participant — 42.2; 59.1; 51.0 % negative specimens per participant — p=0.177
Stimulant Dependence
Primary: Stroop Color-word Task — 55.4; 50.5 seconds
Cannabis · Cannabis Use
Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants